Group 1 - The core point of the article is the resignation of the financial director and the appointment of a new financial director at Guangyuyuan Pharmaceutical Co., Ltd. due to work adjustments [1] - The board of directors received resignation reports from financial director Wang Junbo and vice president Ren Yan, with Wang Junbo remaining as vice president [1] - The board's nomination committee and audit committee approved the proposal to appoint Ren Yan as the new financial director, with a term until the end of the eighth board of directors [1] Group 2 - For the first half of 2025, Guangyuyuan's revenue composition is as follows: pharmaceutical industry accounts for 89.39%, other businesses 3.85%, and health wine 3.29% [1]

Group 1 - The company Guangyuyuan announced the appointment of Ren Yan as the Chief Financial Officer [2][3]

证券代码：600771 证券简称：广誉远 公告编号：2025-016 广誉远中药股份有限公司 关于财务总监、副总裁离任暨聘任财务总监的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广誉远中药股份有限公司（以下简称"公司"）董事会近日分别收到财务总 监王俊波、副总裁任岩的辞职报告，因工作调整原因，王俊波不再担任公司财务 总监，仍担任公司副总裁；任岩不再担任公司副总裁。根据相关规定，王俊波、 任岩的辞职报告自送达董事会之日起生效。 一、高级管理人员离任情况 | | | 离任职务 | 离任时间 | | | 原定任期 | | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | | | | | | 到期日 | | | | （如适用） | 履行完毕的 | | | | | | | | | | | 股子公司任职 | | 公开承诺 | | ...

证券代码：600771 证券简称：广誉远 编号：临 2025-017 广誉远中药股份有限公司 关于控股子公司缴纳税款及滞纳金的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司（以下简称"公司"）控股子公司西藏广誉远药业有限公 司（以下简称"西藏广誉远"）近期进行自查，西藏广誉远需补缴税款及滞纳金，现将 有关情况公告如下： 一、本次补缴税款及滞纳金的基本情况 经自查，西藏广誉远需补缴企业所得税 23,971,187.08 元及滞纳金 5,694,189.2 元， 共计 29,665,376.28 元。截至本公告出具日，西藏广誉远已将上述税款及滞纳金缴纳 完毕。 本次补缴不属于公司主观造成的偷税、漏税情况，不涉及税务行政处罚。 二、对公司的影响 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相关规定， 上述补缴税款及滞纳金事项不属于前期会计差错，不涉及前期财务数据追溯调整。西藏 广誉远补缴税款及滞纳金全部计入 2025 年当期损益，对公司 2025 年度净利润的影响最 终 ...

Group 1 - The company is actively working on the "Guilingji Wine Restructuring" project, focusing on improving the quality of the base liquor, taste, packaging design, and standardizing product technology [2] - The company has developed a diverse product matrix, including flavored Guilingji medicinal wine, Yuanzipai Guilingji health wine, Guiling liquor, and white liquor [2] - The company is committed to long-term research on any matters that benefit its development and product improvement, aiming to establish a solid foundation for enhancing operational quality [2]

Group 1 - The company experienced poor performance in Q2 last year and an even worse sequential decline in Q2 this year despite significant marketing expenditures [1] - The company aims to enhance brand awareness, expand market share, and improve product competitiveness through its marketing investments [1] - The board of directors emphasizes the importance of market capitalization management and has implemented a trial market capitalization management system [1] Group 2 - The company has positioned its brand as "Guangyuyuan National Medicine, Premium Health Products" and has tailored strategies for different products and channels [1] - The company assures that all operations are proceeding normally and production activities are on track [1] - The company encourages stakeholders to pay attention to official announcements regarding the appointment of directors and senior management personnel [1]

Core Viewpoint - The company, Guangyuyuan, operates independently and has no business cooperation with Dongsheng Group or related companies, despite Dongsheng Group being one of its top ten shareholders [1] Group 1 - Dongsheng Group is listed as one of the top ten shareholders of Guangyuyuan [1] - Guangyuyuan emphasizes its independence in business operations, management, strategic decisions, and business expansion [1] - The company's activities are aimed at benefiting its development and creating value for all shareholders, ensuring legality and compliance [1]

Group 1 - The core viewpoint is that the company has struggled to meet shareholder expectations regarding the sales revenue of its health wine, which only reached slightly over 20 million [1] - The company has been promoting the concept of "Turtle Wine Restructuring" for several years, indicating a long-term challenge ahead [1] - The suggestion from investors is for the company to consider following the marketing strategies of a competitor, Jinjiu, to improve sales [1]

Group 1 - The independent director system plays a significant role in promoting standardized operations of listed companies, protecting the legitimate rights of small and medium investors, and fostering the healthy and stable development of the capital market [1] - According to the 2024 A-share independent director data report, among over ten thousand independent directors in A-shares, the highest remuneration is 1.07 million yuan, with 217 independent directors not receiving any remuneration, and the lowest remuneration being 9,600 yuan. Additionally, 61 independent directors earn over 500,000 yuan, while 6,545 earn less than 100,000 yuan [1] - There are over 2,000 independent directors aged 65 and above, with 23 being over 80 years old, and more than 3,500 aged between 60 and 69 [1] Group 2 - Zhao Xuanmin, an independent director of Guangyuyuan, was penalized by regulators in 2024 with a fine of 500,000 yuan. Over the five years from 2020 to 2024, he received a total remuneration of 472,000 yuan from Guangyuyuan, resulting in a net loss of 28,000 yuan after the penalty [1] - The Shanxi Securities Regulatory Bureau announced that Guangyuyuan's annual reports from 2016 to 2021 contained false disclosures regarding the "buyout sales" model, leading to premature revenue recognition and incorrect handling of sales expenses [2] - Zhao Xuanmin holds a PhD in management from Northwest A&F University and has served in various accounting and financial roles, including as an independent director for multiple companies [2]

Core Viewpoint - Guangyuyuan's stock price has shown a mixed performance in 2023, with a year-to-date increase of 7.85% but a recent decline over various trading periods, indicating potential volatility in investor sentiment [2]. Company Overview - Guangyuyuan, established on November 25, 1996, and listed on November 5, 1996, is located in Taiyuan, Shanxi Province. The company specializes in the production and sale of traditional Chinese medicine, premium Chinese medicine, and health wine [2]. - The revenue composition of Guangyuyuan is as follows: traditional Chinese medicine 72.19%, premium Chinese medicine 24.20%, health wine 3.55%, and other (supplementary) 0.06% [2]. - As of June 30, 2025, Guangyuyuan had 63,500 shareholders, a decrease of 5.12% from the previous period, with an average of 7,708 circulating shares per shareholder, an increase of 5.40% [2]. Financial Performance - For the first half of 2025, Guangyuyuan reported a revenue of 779 million yuan, representing a year-on-year growth of 18.14%. The net profit attributable to shareholders was 76.86 million yuan, reflecting a year-on-year increase of 28.95% [2]. - Since its A-share listing, Guangyuyuan has cumulatively distributed cash dividends amounting to 12.71 million yuan, with no dividends paid in the last three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders of Guangyuyuan include Hong Kong Central Clearing Limited as the third-largest shareholder with 5.6151 million shares, a new addition. Southern CSI 1000 ETF ranks fourth with 4.5139 million shares, an increase of 857,400 shares from the previous period [3]. - Other notable shareholders include Huaxia CSI 1000 ETF with 2.6639 million shares (an increase of 632,000 shares) and Nuon Pioneer Mixed A as a new shareholder with 2.6518 million shares [3].